This video-based case study will explore the current landscape of HER2-targeted approaches in NSCLC, including the role of ADCs and managing their associated treatment-related toxicities. Key clinical trial data on the efficacy and safety of HER2-directed therapies in patients with HER2 mutations or HER2 overexpression will be covered, delivering practical support for patient selection and treatment sequencing.
If you do not have an existing account, you will be sent to the Springer Medicine log in page to start the video. You will only need to register once for full access to all content across all our programs.
Title: Case navigator: HER2-targeted therapies in practice
Release date: August 13, 2026
Expiration date: August 13, 2027
Estimated time to complete activity: 15 minutes
This program is intended for oncologists, pathologists, pulmonologists and oncology nurses, physician assistants, and those in the multidisciplinary teams worldwide who provide front-line care for patients with NSCLC.
Following completion of this independent educational program, you will be able to:
Credits available
Completing one Case Navigator activity will earn you 0.25 AMA PRA Category 1 Credit(s)™. You can earn a total of 0.5 credits for both activities.
In support of improving patient care, this activity has been planned and implemented by Postgraduate Institute for Medicine and Springer Healthcare IME. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
As part of the planning committee Katie Long and Jules Morgan have no interests to disclose. The PIM staff has no financial relationships to disclose. All relevant financial relationships have been mitigated.
